See more : Vesuvius India Limited (VESUVIUS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Thermo Fisher Scientific Inc. (TMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermo Fisher Scientific Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Cooper Metals Limited (CPM.AX) Income Statement Analysis – Financial Results
- ELES Semiconductor Equipment S.p.A. (ELES.MI) Income Statement Analysis – Financial Results
- Schroders plc (SHNWF) Income Statement Analysis – Financial Results
- Hanjin Transportation Co., Ltd. (002320.KS) Income Statement Analysis – Financial Results
- London Stock Exchange Group plc (LNSTY) Income Statement Analysis – Financial Results
Thermo Fisher Scientific Inc. (TMO)
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.86B | 44.92B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B | 16.97B | 16.89B | 13.09B | 12.51B | 11.73B | 10.79B | 10.11B | 10.50B | 9.75B | 3.79B | 2.63B | 2.21B | 2.10B | 2.09B | 2.19B | 2.28B | 2.47B | 3.87B | 3.56B | 2.93B | 2.21B | 1.59B | 1.25B | 949.00M | 805.50M | 708.00M | 579.00M | 500.60M | 383.40M | 331.60M | 265.70M |
| Cost of Revenue | 25.74B | 25.42B | 18.98B | 15.71B | 13.72B | 12.99B | 10.96B | 9.46B | 8.78B | 8.97B | 7.34B | 6.99B | 6.74B | 6.22B | 5.96B | 6.29B | 5.94B | 2.22B | 1.44B | 1.19B | 1.15B | 1.16B | 1.23B | 1.26B | 1.26B | 2.02B | 1.84B | 1.54B | 1.12B | 866.30M | 713.10M | 579.80M | 510.20M | 443.00M | 384.10M | 325.70M | 248.70M | 219.30M | 174.30M |
| Gross Profit | 17.11B | 19.50B | 20.23B | 16.51B | 11.83B | 11.36B | 9.96B | 8.82B | 8.18B | 7.92B | 5.75B | 5.52B | 4.99B | 4.57B | 4.15B | 4.21B | 3.80B | 1.57B | 1.19B | 1.01B | 948.02M | 927.38M | 958.62M | 1.02B | 1.21B | 1.84B | 1.72B | 1.39B | 1.08B | 719.00M | 536.60M | 369.20M | 295.30M | 265.00M | 194.90M | 174.90M | 134.70M | 112.30M | 91.40M |
| Gross Profit Ratio | 39.93% | 43.42% | 51.60% | 51.23% | 46.30% | 46.65% | 47.60% | 48.24% | 48.23% | 46.89% | 43.93% | 44.10% | 42.54% | 42.39% | 41.04% | 40.07% | 39.03% | 41.36% | 45.38% | 45.99% | 45.21% | 44.45% | 43.81% | 44.81% | 48.81% | 47.65% | 48.36% | 47.40% | 49.05% | 45.35% | 42.94% | 38.90% | 36.66% | 37.43% | 33.66% | 34.94% | 35.13% | 33.87% | 34.40% |
| Research & Development | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B | 967.00M | 888.00M | 754.80M | 692.30M | 691.10M | 395.50M | 376.40M | 340.60M | 287.20M | 246.10M | 249.10M | 238.70M | 170.18M | 152.78M | 134.68M | 146.39M | 155.12M | 171.61M | 176.76M | 171.10M | 367.30M | 337.30M | 0.00 | 269.60M | 103.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.45B | 7.13B | 6.84B | 5.76B | 4.93B | 4.82B | 4.41B | 4.04B | 3.72B | 3.99B | 2.91B | 2.83B | 2.65B | 2.39B | 2.20B | 2.69B | 2.55B | 1.11B | 761.79M | 626.46M | 568.14M | 564.66M | 620.10M | 646.92M | 673.00M | 937.60M | 840.70M | 990.70M | 480.80M | 373.20M | 370.60M | 271.70M | 233.60M | 210.60M | 164.40M | 144.60M | 117.10M | 91.60M | 78.70M |
| Other Expenses | 536.00M | 2.40B | 1.76B | 1.67B | 1.71B | 9.00M | -28.00M | -4.10M | -15.50M | 16.40M | -56.00M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| Operating Expenses | 10.24B | 10.99B | 10.01B | 8.61B | 7.65B | 7.53B | 6.89B | 6.18B | 5.73B | 6.01B | 4.06B | 3.95B | 3.64B | 3.25B | 3.04B | 2.94B | 2.79B | 1.28B | 914.56M | 761.14M | 714.53M | 719.78M | 791.72M | 823.68M | 957.70M | 1.47B | 1.31B | 1.11B | 835.40M | 539.20M | 413.00M | 300.90M | 257.00M | 229.40M | 177.10M | 155.70M | 127.20M | 100.00M | 86.50M |
| Cost & Expenses | 36.00B | 36.41B | 28.99B | 24.33B | 21.36B | 20.53B | 17.85B | 15.64B | 14.51B | 14.98B | 11.40B | 10.95B | 10.38B | 9.46B | 9.00B | 9.23B | 8.73B | 3.50B | 2.35B | 1.95B | 1.86B | 1.88B | 2.02B | 2.08B | 2.22B | 3.49B | 3.15B | 2.65B | 1.96B | 1.41B | 1.13B | 880.70M | 767.20M | 672.40M | 561.20M | 481.40M | 375.90M | 319.30M | 260.80M |
| Interest Income | 879.00M | 272.00M | 43.00M | 65.00M | 224.00M | 137.00M | 81.00M | 48.40M | 30.60M | 47.70M | 28.00M | 25.20M | 26.90M | 12.50M | 16.10M | 51.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M | 592.00M | 469.60M | 414.90M | 479.90M | 262.10M | 241.60M | 175.30M | 84.70M | 118.10M | 151.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 999.90M | 983.70M | 863.50M | 770.00M | 787.30M | 792.70M | 756.80M | 240.77M | 123.27M | 66.14M | 58.55M | 56.38M | 98.52M | 97.49M | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| EBITDA | 11.20B | 11.94B | 12.96B | 10.19B | 6.46B | 6.20B | 5.25B | 4.25B | 4.04B | 4.25B | 2.58B | 2.49B | 2.18B | 1.91B | 1.83B | 2.07B | 1.78B | 502.07M | 435.89M | 336.34M | 279.30M | 193.08M | 265.43M | 295.65M | 362.20M | 353.40M | 371.60M | 399.40M | 332.30M | 242.10M | 166.00M | 97.50M | 61.70M | 54.40M | 30.50M | 30.30M | 17.60M | 20.70M | 12.70M |
| EBITDA Ratio | 26.12% | 26.84% | 31.03% | 31.67% | 25.88% | 25.64% | 24.62% | 24.30% | 24.49% | 21.63% | 20.31% | 20.60% | 19.07% | 19.54% | 18.92% | 19.95% | 18.65% | 15.11% | 14.55% | 14.22% | 14.63% | 9.25% | 16.53% | 13.55% | 23.20% | 13.51% | 12.97% | 10.53% | 9.21% | 10.02% | 12.68% | 4.16% | 0.30% | 2.53% | -0.14% | 1.96% | -1.85% | 3.44% | 0.45% |
| Operating Income | 6.86B | 8.39B | 10.03B | 7.79B | 4.59B | 3.78B | 2.97B | 2.45B | 2.34B | 2.50B | 1.61B | 1.48B | 1.25B | 1.26B | 1.05B | 1.23B | 974.40M | 241.96M | 263.49M | 237.51M | 184.77M | 155.45M | 34.20M | 198.16M | 248.60M | 375.80M | 407.00M | 284.20M | 247.30M | 179.80M | 123.60M | 68.30M | 38.30M | 35.60M | 17.80M | 19.20M | 7.50M | 12.30M | 4.90M |
| Operating Income Ratio | 16.00% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.19% | 13.40% | 13.77% | 14.82% | 12.30% | 11.85% | 10.62% | 11.72% | 10.38% | 11.71% | 10.00% | 6.38% | 10.01% | 10.77% | 8.81% | 7.45% | 1.56% | 8.69% | 10.06% | 9.72% | 11.44% | 9.69% | 11.20% | 11.34% | 9.89% | 7.20% | 4.75% | 5.03% | 3.07% | 3.84% | 1.96% | 3.71% | 1.84% |
| Total Other Income/Expenses | -561.00M | -558.00M | -1.19B | -567.00M | -524.00M | -521.00M | -531.00M | -434.10M | -399.60M | -415.80M | -290.10M | -212.70M | -112.40M | -100.30M | -121.80M | -79.80M | -93.10M | -32.59M | -7.88M | 4.78M | 35.25M | 131.50M | 42.32M | -23.90M | -230.10M | -28.30M | -100.30M | 17.40M | -8.30M | -7.20M | -13.60M | 19.80M | 33.70M | 15.40M | 16.40M | 8.20M | 15.20M | 4.90M | 6.90M |
| Income Before Tax | 6.30B | 7.84B | 8.84B | 7.23B | 4.07B | 3.26B | 2.43B | 2.02B | 1.94B | 2.09B | 1.32B | 1.27B | 1.13B | 1.16B | 927.10M | 1.15B | 881.30M | 209.37M | 285.90M | 259.22M | 218.63M | 287.99M | 76.52M | 174.26M | 18.50M | 347.50M | 414.00M | 301.60M | 239.00M | 172.60M | 110.00M | 88.10M | 72.00M | 51.00M | 34.20M | 27.40M | 22.70M | 17.20M | 11.80M |
| Income Before Tax Ratio | 14.70% | 17.44% | 22.55% | 22.43% | 15.93% | 13.39% | 11.61% | 11.08% | 11.41% | 12.36% | 10.08% | 10.15% | 9.61% | 10.79% | 9.17% | 10.95% | 9.04% | 5.52% | 10.86% | 11.75% | 10.43% | 13.80% | 3.50% | 7.64% | 0.75% | 8.98% | 11.63% | 10.28% | 10.83% | 10.89% | 8.80% | 9.28% | 8.94% | 7.20% | 5.91% | 5.47% | 5.92% | 5.19% | 4.44% |
| Income Tax Expense | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M | 324.00M | 201.00M | -1.40M | -43.90M | 191.70M | 40.40M | 11.00M | 107.00M | 131.50M | 75.80M | 160.90M | 101.70M | 43.05M | 87.60M | 40.85M | 45.94M | 92.99M | 26.93M | 112.22M | 33.10M | 170.70M | 174.70M | 110.80M | 98.90M | 69.20M | 33.40M | 27.50M | 24.90M | 17.10M | 9.60M | 7.30M | 4.60M | 2.90M | 2.20M |
| Net Income | 6.00B | 6.95B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B | 1.98B | 1.89B | 1.27B | 1.18B | 1.33B | 1.04B | 850.30M | 994.20M | 761.10M | 168.94M | 223.22M | 361.84M | 200.01M | 309.73M | -781.00K | -36.11M | -174.60M | 181.90M | 239.30M | 190.80M | 140.10M | 103.40M | 76.60M | 59.20M | 47.10M | 33.90M | 24.60M | 20.10M | 18.10M | 14.30M | 9.60M |
| Net Income Ratio | 13.99% | 15.47% | 19.70% | 19.79% | 14.47% | 12.06% | 10.64% | 11.06% | 11.64% | 11.22% | 9.73% | 9.42% | 11.34% | 9.60% | 8.41% | 9.47% | 7.81% | 4.46% | 8.48% | 16.40% | 9.54% | 14.85% | -0.04% | -1.58% | -7.07% | 4.70% | 6.73% | 6.51% | 6.35% | 6.52% | 6.13% | 6.24% | 5.85% | 4.79% | 4.25% | 4.02% | 4.72% | 4.31% | 3.61% |
| EPS | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.64 | 5.12 | 4.96 | 4.76 | 3.53 | 3.24 | 3.49 | 2.57 | 2.06 | 2.34 | 1.81 | 0.86 | 1.38 | 2.22 | 1.23 | 1.84 | 0.00 | -0.22 | -1.11 | 1.12 | 1.57 | 1.35 | 1.11 | 0.93 | 0.33 | 0.18 | 0.17 | 0.14 | 0.11 | 0.10 | 0.09 | 0.07 | 0.04 |
| EPS Diluted | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 | 5.09 | 4.92 | 4.71 | 3.48 | 3.21 | 3.46 | 2.53 | 2.01 | 2.25 | 1.72 | 0.84 | 1.36 | 2.17 | 1.20 | 1.73 | 0.00 | -0.22 | -1.10 | 1.08 | 1.41 | 1.22 | 0.99 | 0.82 | 0.29 | 0.17 | 0.16 | 0.13 | 0.10 | 0.09 | 0.09 | 0.07 | 0.04 |
| Weighted Avg Shares Out | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M | 395.00M | 394.80M | 398.70M | 398.20M | 360.30M | 363.80M | 380.80M | 403.30M | 412.40M | 418.20M | 421.50M | 196.10M | 161.59M | 163.13M | 162.71M | 168.33M | 181.59M | 164.14M | 157.99M | 162.41M | 152.48M | 141.53M | 125.48M | 110.80M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
| Weighted Avg Shares Out (Dil) | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M | 398.00M | 397.40M | 401.90M | 402.30M | 365.80M | 366.60M | 384.80M | 409.40M | 423.03M | 434.70M | 443.70M | 203.70M | 165.33M | 167.64M | 170.73M | 179.03M | 185.02M | 164.14M | 158.22M | 168.43M | 169.79M | 175.70M | 158.10M | 145.53M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
Will These 3 MedTech Stocks Surpass Q3 Earnings Forecasts?
Here is a sneak peek into how three MedTech stocks, BSX, TMO and ALGN, are expected to fare in their third-quarter results, slated to be released tomorrow.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Lab Consumables Business Research Report 2024-2030 with Focus on 350+ Select Players Including Thermo Fisher Scientific, VITLAB, Bellco Glass, Eppendorf and BRAND Scientific Equipment Among Others
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Lab Consumables - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Lab Consumables is estimated at US$12.7 Million in 2023 and is projected to reach...
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, introduced a groundbreaking transmission electron microscope to a packed room of attendees at the recent European Microscopy Congress 2024 in Copenhagen, Denmark. As a fully integrated multimodal analytical...
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Source: https://incomestatements.info
Category: Stock Reports